Key market opportunities include the rising prevalence of chronic diseases and increased regulatory approvals driving demand ...
PITTSBURGH, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (KRYS) (the “Company”) (NASDAQ: KRYS) announced today that the United States Food and Drug Administration (FDA) granted platform ...
In July 2025, a class 2 resubmission of tab-cel’s BLA was initiated by Atara Biotherapeutics, developer and sponsor of ...
Inovio’s upside hinges on INO-3107 for HPV-6/11 RRP with FDA PDUFA Oct 2026, regulatory risk, tight cash, and cheap EV. Check out why INO stock is a buy.
After greenlighting 56 novel therapeutics in 2025, four notable applications continue to await the agency’s action after ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results